Page 35 - Stroke Statistics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail DALLAS, April 6, 2021 -- A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. These are the opinions of two esteemed leaders in cardiovascular disease care, research and strategy, detailed in two new Frame of Reference articles published today in the ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce ... Amarin Corporation plcMarch 17, 2021 GMT 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke obser...

Share: 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Awa...

Share this article Share this article NEW YORK, March 15, 2021 /PRNewswire/ -- One of the key reasons behind the growth of the global  external defibrillator market is the rise in the prevalence of cardiovascular diseases (CVDs). As a result, the revenue generated from the sale of such devices is predicted to reach $9,450.3 million by 2030, from $3,926.5 million in 2019, at an 8.5% CAGR between 2020 and 2030, according to P&S Intelligence. According to the Heart Disease and Stroke Statistics—2017 Update report published by the American Heart Association (AHA), 800,000, or one in every thr...

Pharmacists must ascertain the appropriateness of use and screen for potential contraindications and drug interactions.